Ovarian Cancer Platinum Resistance: Mechanisms, Targets, and Personalized Treatment

Ovarian cancer, a prevalent malignant tumor, is commonly treated with platinum-based drugs as the first-line therapy. However, the increasing use of these drugs has led to a rise in platinum resistance. Statistics indicate that approximately 30-50% of ovarian cancer patients develop resistance to platinum-based drugs after treatment. Consequently, it is crucial to investigate platinum resistance in ovarian cancer, as comprehending its mechanisms can enhance our understanding of the disease's progression.

Currently, platinum resistance is believed to be influenced by various factors, such as the cell's DNA repair capacity, cell apoptosis pathway, and expression of transport proteins. Thorough research into these mechanisms can provide valuable insights for discovering novel treatment strategies. The development of platinum resistance often involves the abnormal activation of intracellular signaling pathways. Hence, exploring platinum resistance in ovarian cancer can aid in identifying new therapeutic targets and drugs.

Furthermore, understanding the extent of platinum resistance in ovarian cancer is advantageous for the clinical formulation of personalized treatment plans. Different patients exhibit varying levels of resistance to platinum-based drugs. Therefore, comprehending a patient's resistance profile can assist doctors in selecting more appropriate treatment options and enhancing treatment efficacy.